KineMed Inc. announced that it has entered into a strategic collaboration with Pfizer Inc. to discover and develop novel proprietary biomarkers in various fields of unmet medical need. KineMed’s platform technology provides a proprietary, rate-based approach for developing novel biomarkers. By utilising mass spectroscopy and stable isotope labeling of protein turnover, KineMed biomarkers provide rates of change of key proteins involved with therapeutic efficacy and target engagement.

Under the terms of the agreement, Pfizer has licensed access to the KineMed platform and rights to pursue discovery, development and potential commercialisation of kinetic biomarkers in various fields. Both companies will work together on discovery research of novel biomarkers, and Pfizer will be responsible for the development and potential commercialisation of any novel biomarkers or companion diagnostics for the Pfizer-selected targets.

KineMed will receive an upfront payment, as well as funding for research and development costs associated with Pfizer-selected targets. In addition, KineMed is eligible to receive development and regulatory milestone payments.

“We believe our kinetic biomarker platform provides real advantages over other approaches to biomarker discovery in de-risking and advancing medicines development, and this collaboration with Pfizer is an important step toward helping us realize the full potential of this technology,” said Patrick Doyle, president at KineMed.

KineMed has developed and validated a proprietary drug development platform to clinically advance drugs more efficiently and with less risk for later sale/out-license. The company is creating a pipeline of high value drug assets in muscle-wasting and fibrotic diseases. The pipeline today is focused on phase 2 trials with synthetic Ghrelin, to address CKD & muscle wasting in the elderly.

KineMed intends to clinically advance multiple pipeline drug assets – in-licensed, partnered or acquired – for subsequent out-licensing after value has been added through our rapid phase 2 trials.